Skip to main content

Bicycle Therapeutics plc

corporate_fare Company Profile

Bicycle Therapeutics plc

BCYC·NASDAQ·Life Sciences·CIK 0001761612

We are a clinical-stage pharmaceutical company developing a novel class of medicines called Bicycle® molecules for diseases not adequately addressed by current treatments. Bicycle molecules are fully synthetic short peptides constrained into two loops, stabilizing their structure. This constraint enables high-affinity and selective target binding, making them suitable for drug development. Bicycle molecules combine the pharmacological characteristics of biologics with the manufacturing and pharmacokinetic (PK) properties of small molecules. Their relatively large surface area allows them to target areas historically difficult for non-biological approaches. Bicycle molecules are excreted by the kidney, not the liver, and have shown no significant immunogenicity to date. We use a novel and proprietary phage display screening platform to efficiently identify Bicycle molecules. This platform initially displays linear peptides on engineered bacteriophages, or phages, followed by "on-phage" cyclization with small molecule scaffolds. Our platform encodes quintillions of potential Bicycle molecules for screening and optimization into product candidates. We have used this technology to identify our current oncology candidates and plan to use it with collaborators for future candidates in other disease areas. Our internal programs focus on oncology indications with high unmet medical need. Our product candidate, nuzefatide pevedotin (formerly BT5528), is a Bicycle Drug Conjugate (BDC® molecule), where the Bicycle molecule is chemically linked to a toxin that, upon administration, cleaves from the Bicycle molecule to kill tumor cells.

Bicycle Therapeutics plc (NASDAQ:BCYC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for BCYC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for BCYC spans 10-Q, 8-K, PRE 14A, 10-K.

Recent high-impact activity:

  • Bicycle Therapeutics Narrows Q3 Loss to $10.5M as Bayer Revenue Lifts Top Line
  • Bicycle Therapeutics Narrows Q2 Loss, Extends Cash Runway to 2030
  • Bicycle Therapeutics Q2 2026: $50.3M Loss, Bayer Collaboration Terminated, Pipeline Reprioritized
  • Bicycle Therapeutics' Duravelo-2 Trial Shows Lower Toxicity, Comparable Efficacy in mUC
  • Bicycle Therapeutics Reports Positive Phase 2 Duravelo-2 Data for Zelenectide in Urothelial Cancer

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$72.59M
Net Income
-$218.96M
Diluted EPS
-$3.16
Op. Cash Flow
-$249.68M
Free Cash Flow
-$252.03M
Operating Income
-$247.06M
Cash & Equivalents
$628.11M
Debt / Equity
0.00×
Net Margin
-301.7%
Shares Outstanding
69.37M sh
Source: 10-K · filed 2026-03-17 · accession 0001104659-26-028971

Short Interest & Short Volume

8.38 days to cover

FINRA reported short interest of 3,858,686 shares in BCYC as of the October 30, 2026 settlement, a 11.8% increase from the prior period — about 8.4 days to cover at its recent average daily volume. On November 20, 2026, 57.0% of BCYC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,858,686 shares as of October 30, 2026
Change vs prior period▲ 11.8%
Days to cover8.38 at avg daily volume of 460,266
Daily short volume (FINRA facilities)57.0% of 420,132 shares on November 20, 2026
5-day average short volume50.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with B →
$2.9
52-week range · as of 2026-07-30 $2.9 – $9.16
Market cap
$202.98M
Volume
1M (2.3× avg)
3-mo avg 450.1K
Live data · 2026-11-22 05:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BCYC - Latest Insights

BCYC
Oct 29, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $3.85
Real-time Price: $2.90 info
Change: -$0.950 (-25%) info
Market Cap: $202.98M info
BCYC
Jul 30, 2026, 7:38 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.82
Real-time Price: $2.90 info
Change: -$0.920 (-24%) info
Market Cap: $202.98M info
BCYC
Jul 30, 2026, 7:10 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.82
Real-time Price: $2.90 info
Change: -$0.920 (-24%) info
Market Cap: $202.98M info
BCYC
May 21, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $4.40
Real-time Price: $2.90 info
Change: -$1.50 (-34%) info
Market Cap: $202.98M info
BCYC
May 21, 2026, 5:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.40
Real-time Price: $2.90 info
Change: -$1.50 (-34%) info
Market Cap: $202.98M info
BCYC
Apr 30, 2026, 7:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.70
Real-time Price: $2.90 info
Change: -$1.80 (-38%) info
Market Cap: $202.98M info
BCYC
Apr 30, 2026, 7:10 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.50
Real-time Price: $2.90 info
Change: -$1.60 (-36%) info
Market Cap: $202.98M info
BCYC
Apr 30, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.50
Real-time Price: $2.90 info
Change: -$1.60 (-36%) info
Market Cap: $202.98M info
BCYC
Apr 20, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.30
Real-time Price: $2.90 info
Change: -$2.40 (-45%) info
Market Cap: $202.98M info
BCYC
Apr 03, 2026, 4:06 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $5.00
Real-time Price: $2.90 info
Change: -$2.10 (-42%) info
Market Cap: $202.98M info
BCYC
Mar 17, 2026, 7:19 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $4.80
Real-time Price: $2.90 info
Change: -$1.90 (-40%) info
Market Cap: $202.98M info
BCYC
Mar 17, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.80
Real-time Price: $2.90 info
Change: -$1.90 (-40%) info
Market Cap: $202.98M info
BCYC
Feb 03, 2026, 7:07 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.40
Real-time Price: $2.90 info
Change: -$3.50 (-55%) info
Market Cap: $202.98M info
BCYC
Jan 12, 2026, 7:12 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.69
Real-time Price: $2.90 info
Change: -$3.79 (-57%) info
Market Cap: $202.98M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets